Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Vitamin D and lumisterol novel metabolites can inhibit SARS-CoV-2 replication machinery enzymes

Qayyum et al., Endocrinology and Metabolism, doi:10.1152/ajpendo.00174.2021
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
In Silico analysis showing that vitamin D and lumisterol metabolites may inhibit SARS-CoV-2 Mpro and RdRP.
Vitamin D has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function EFSA, EFSA (B), Galmés, Galmés (B). Vitamin D inhibits SARS-CoV-2 replication in vitro Campolina-Silva, Pickard, mitigates lung inflammation, damage, and lethality in mice with an MHV-3 model for β-CoV respiratory infections Campolina-Silva, Pickard, reduces SARS-CoV-2 replication in nasal epithelial cells via increased type I interferon expression Sposito, downregulates proinflammatory cytokines IL-1β and TNF-α in SARS-CoV-2 spike protein-stimulated cells Alcalá-Santiago, may be neuroprotective by protecting the blood-brain barrier, reducing neuroinflammation, and via immunomodulatory effects Gotelli, and improves regulatory immune cell levels and control of proinflammatory cytokines in severe COVID-19 Saheb Sharif-Askari. Symptomatic COVID-19 is associated with a lower frequency of natural killer (NK) cells and vitamin D has been shown to improve NK cell activity Graydon, Oh.
Qayyum et al., 27 Jul 2021, peer-reviewed, 7 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperVitamin DAll
Vitamin D and lumisterol novel metabolites can inhibit SARS-CoV-2 replication machinery enzymes
Shariq Qayyum, Taj Mohammad, Radomir M Slominski, Md Imtaiyaz Hassan, Robert C Tuckey, Chander Raman, Andrzej T Slominski
American Journal of Physiology-Endocrinology and Metabolism, doi:10.1152/ajpendo.00174.2021
Vitamin D deficiency significantly correlates with the severity of SARS-CoV-2 infection. Molecular docking-based virtual screening studies predict that novel vitamin D and related lumisterol hydroxymetabolites are able to bind to the active sites of two SARS-CoV-2 transcription machinery enzymes with high affinity. These enzymes are the main protease (M pro ) and RNA-dependent RNA polymerase (RdRP), which play important roles in viral replication and establishing infection. Based on predicted binding affinities and specific interactions, we identified 10 vitamin D3 (D3) and lumisterol (L3) analogs as likely binding partners of SARS-CoV-2 M pro and RdRP and, therefore, tested their ability to inhibit these enzymes. Activity measurements demonstrated that 25 (OH)L3, 24(OH)L3, and 20(OH)7DHC are the most effective of the hydroxymetabolites tested at inhibiting the activity of SARS-CoV-2 M pro causing 10%-19% inhibition. These same derivatives as well as other hydroxylumisterols and hydroxyvitamin D3 metabolites inhibited RdRP by 50%-60%. Thus, inhibition of these enzymes by vitamin D and lumisterol metabolites may provide a novel approach to hindering the SARS-CoV-2 infection. NEW & NOTEWORTHY Active forms of vitamin D and lumisterol can inhibit SARS-CoV-2 replication machinery enzymes, which indicates that novel vitamin D and lumisterol metabolites are candidates for antiviral drug research.
References
Bikle, Vitamin D: newer concepts of its metabolism and function at the basic and clinical level, J Endocr Soc, doi:10.1210/jendso/bvz038
Coussens, Naude, Goliath, Chaplin, Wilkinson et al., High-dose vitamin D3 reduces deficiency caused by low UVB exposure and limits HIV-1 replication in urban Southern Africans, Proc Natl Acad Sci, doi:10.1073/pnas.1500909112
Dai, Zhang, Jiang, Su, Li et al., Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease, Science, doi:10.1126/science.abb4489
Grant, Anouti, Moukayed, Targeted 25-hydroxyvitamin D concentration measurements and vitamin D3 supplementation can have important patient and public health benefits, Eur J Clin Nutr, doi:10.1038/s41430-020-0564-0
Haussler, Jurutka, Mizwicki, Norman, Vitamin D receptor (VDR)-mediated actions of 1a, 25 (OH) 2vitamin D3: genomic and non-genomic mechanisms, Best Pract Res Clin Endocrinol Metab, doi:10.1016/j.beem.2011.05.010
Holick, Vitamin D: a millenium perspective, J Cell Biochem, doi:10.1002/jcb.10338
Lung, Lin, Yang, Chou, Shu et al., The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase, Erratum in J Med Virol, doi:10.1002/jmv.25761
Maghbooli, Sahraian, Ebrahimi, Pazoki, Kafan et al., Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/ mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection, PLoS One, doi:10.1371/journal.pone.0239799
Mohammad, Shamsi, Anwar, Umair, Hussain et al., Identification of high-affinity inhibitors of SARS-CoV-2 main protease: towards the development of effective COVID-19 therapy, Virus Res, doi:10.1016/j.virusres.2020.198102
Mok, Ng, Ahidjo, Lee, Loe et al., Calcitriol, the active form of vitamin D, is a promising candidate for COVID-19 prophylaxis, bioRxiv, doi:10.1101/2020.06.21.16239
Naqvi, Fatima, Mohammad, Fatima, Singh et al., Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach, Biochim Biophys Acta Mol Basis Dis, doi:10.1016/j.bbadis.2020.165878
Quesada-Gomez, Entrenas-Castillo, Bouillon, Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: revised Ms SBMB 2020_166, J Steroid Biochem Mol Biol, doi:10.1016/j.jsbmb.2020.105719
Rhodes, Subramanian, Laird, Griffin, Kenny, Perspective: vitamin D deficiency and COVID-19 severity-plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis, J Intern Med, doi:10.1111/joim.13149
Shirvani, Kalajian, Song, Holick, Disassociation of vitamin D's calcemic activity and non-calcemic genomic activity and individual responsiveness: a randomized controlled double-blind clinical trial, Sci Rep, doi:10.1038/s41598-019-53864-1
Slominski, Chaiprasongsuk, Janjetovic, Kim, Stefan et al., Photoprotective properties of vitamin D and lumisterol hydroxyderivatives, Cell Biochem Biophys, doi:10.1007/s12013-020-00913-6
Slominski, Kim, Hobrath, Janjetovic, Oak et al., Characterization of a new pathway that activates lumisterol in vivo to biologically active hydroxylumisterols, Sci Rep, doi:10.1038/s41598-017-10202-7
Slominski, Li, Kim, Semak, Wang et al., Novel activities of CYP11A1 and their potential physiological significance, J Steroid Biochem Mol Biol, doi:10.1016/j.jsbmb.2014.11.010
Slominski, Stefan, Athar, Holick, Jetten et al., COVID-19 and Vitamin D: a lesson from the skin, Exp Dermatol, doi:10.1111/exd.14170
Teymoori-Rad, Shokri, Salimi, Marashi, The interplay between vitamin D and viral infections, Rev Med Virol, doi:10.1002/rmv.2032
Tuckey, Cheng, Slominski, The serum vitamin D metabolome: what we know and what is still to discover, J Steroid Biochem Mol Biol, doi:10.1016/j.jsbmb.2018.09.003
Yang, Yang, Ding, Liu, Lou et al., The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor, Proc Natl Acad Sci, doi:10.1073/pnas.1835675100
Yin, Mao, Luan, Shen, Shen et al., Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir, Science, doi:10.1126/science.abc1560
Zhang, Lin, Sun, Curth, Drosten et al., Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors, Science, doi:10.1126/science.abb3405
Zu, Deng, Zhou, Li, Li et al., 25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor, Cell Res, doi:10.1038/s41422-020-00398-1
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit